Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Metoclopramide HCl
Indication
Prophylaxis of chemotherapy-induced nausea and vomiting, Nausea and vomiting, Prophylaxis of nausea and vomiting associated with radiation therapy, Prophylaxis of postoperative nausea and vomiting, Intubation of the small intestine, Premedication for radiologic examination of the upper gastrointestinal tract, Diabetic gastric stasis
Instruction
via IM or slow IV inj
Drug interaction
Additive sedative effects with CNS depressants (e.g. morphine derivatives, anxiolytics, H1-receptor blockers, sedative antidepressants, barbiturates, clonidine). Increased risk of extrapyramidal disorders with other neuroleptic agents or centrally acting drugs (e.g. phenothiazines, tetrabenazine). May increase the risk of serotonin syndrome associated with serotonergic drugs (e.g. SSRIs). May decrease the bioavailability of digoxin. May increase the absorption of ciclosporin, aspirin and paracetamol. May prolong the duration of action of neuromuscular blocking agents (e.g. mivacurium, suxamethonium). Increased serum concentrations with strong CYP2D6 inhibitors (e.g. fluoxetine, paroxetine). Plasma concentrations of atovaquone may be reduced by metoclopramide. Increased risk of QT prolongation with other agents known to prolong QT interval (e.g. class IA and III antiarrhythmics, TCAs, macrolides, antipsychotics). May alter the effects of central stimulants (e.g. sympathomimetics. Increased risk of hypertension with MAO inhibitors. May diminish the effect of antidiabetic agents.Potentially Fatal: Concomitant administration with levodopa or dopamine agonists (e.g. bromocriprine) may result in mutual antagonism.
Malaysia
